Tana, my recollection when I attended a number of investor presentation held by Avexa was a continual belief that ATC as a 2nd line therapy would have a market share of around 20% and would generate approx $500-600M in annual sales.
Others may be able to confirm. There has also been a few posts stating a 20% royalties deal would generate about $100M in revenue for AVX
